 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of [0m
[34mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of [0m
[32mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"BACTRIM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: precautions: Electrolyte Abnormalities Hyperkalemia : High dosage of trimethoprim, as used in patients with P. jirovecii pneumonia, induces a progressive but reversible increase of [0m
[31mserum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause hyperkalemia when trimethoprim is administered to patients with underlying disorders[0m
[31mof potassium metabolism, with renal insufficiency, or if drugs known to induce hyperkalemia are given concomitantly. Close monitoring of serum potassium is warranted in these patients. Hyponatremia : [0m
[31mSevere and symptomatic hyponatremia can occur in patients receiving BACTRIM, particularly for the treatment of P. jirovecii pneumonia. Evaluation for hyponatremia and appropriate correction is [0m
[31mnecessary in symptomatic patients to prevent life-threatening complications. Crystalluria : During treatment, ensure adequate fluid intake and urinary output to prevent crystalluria. BACTRIM: [0m
[31mprecautions: Patients who are ‚Äúslow acetylators‚Äù may be more prone to idiosyncratic reactions to sulfonamides. Information for Patients Patients should be counseled that antibacterial drugs including [0m
[31mBactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets should only be used to treat bacterial infections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Bactrim [0m[1;31m([0m[31msulfamethoxazole and [0m
[31mtrimethoprim[0m[1;31m)[0m[31m tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken [0m
[31mexactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate treatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will [0m
[31mdevelop resistance and will not be treatable by Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets or other antibacterial drugs in the future. BACTRIM: precautions: Patients should be instructed to [0m
[31mmaintain an adequate fluid intake in order to prevent crystalluria and stone formation. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. [0m
[31mSometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the [0m
[31mlast dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests Complete blood counts and clinical chemistry testing should be done [0m
[31mfrequently in patients receiving BACTRIM. Perform urinalyses with careful microscopic examination and renal function tests during therapy, particularly for those patients with impaired renal function.[0m
[31mDiscontinue BACTRIM if a significant electrolyte abnormality, renal insufficiency or reduction in the count of any formed blood element is noted. BACTRIM: drug_interactions: Drug Interactions [0m
[31mPotential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Avoid coadministration of BACTRIM with drugs[0m
[31mthat are substrates of CYP2C8 and 2C9 or OCT2. Table [0m[1;31m1[0m[31m: Drug Interactions with BACTRIM [0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m Recommendation Comments Diuretics Avoid concurrent use In elderly patients concurrently receiving certain[0m
[31mdiuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Warfarin Monitor prothrombin time and INR It has been reported that BACTRIM may prolong the [0m
[31mprothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions: This interaction should be kept in mind when BACTRIM is given to patients [0m
[31malready on anticoagulant therapy, and the coagulation time should be reassessed. Phenytoin Monitor serum phenytoin levels BACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. [0m
[31mBACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic clearance rate by [0m[1;31m27[0m[31m%. When administering these drugs concurrently, one [0m
[31mshould be alert for possible excessive phenytoin effect. Methotrexate Avoid concurrent use Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal [0m
[31mtransport of methotrexate, thus increasing free methotrexate concentrations.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: teratogenic_effects: Teratogenic Effects Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic[0m
[31mstudies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, [0m
[31mcardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple [0m
[31mstatistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures [0m
[31mvaried between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim [0m
[31mexposure and specific malformations. BACTRIM: precautions: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects manifested mainly[0m
[31mas cleft palates. These doses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when [0m[1;31m512[0m[31m mg/kg of [0m
[31msulfamethoxazole was used in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with doses of [0m
[31mtrimethoprim [0m[1;31m6[0m[31m times the human therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast [0m
[31mmilk are approximately [0m[1;31m2[0m[31m‚Äì[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. BACTRIM: precautions: Caution should be exercised when BACTRIM is administered to a nursing woman, [0m
[31mespecially when breastfeeding jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use BACTRIM is contraindicated for [0m
[31minfants younger than [0m[1;31m2[0m[31m months of age [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS sections[0m[1;31m)[0m[31m. Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and [0m
[31mover to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions [0m
[31mexist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. BACTRIM: precautions: Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee[0m
[31mWARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or without purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In[0m
[31mthose concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with [0m
[31mconcomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These [0m
[31meffects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize [0m
[31mrisks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION section[0m[1;31m)[0m[31m. BACTRIM: precautions: The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying [0m
[31mdisorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of [0m
[31mserum potassium is warranted in these patients. Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per[0m
[31mtablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: adverse_reactions: ADVERSE REACTIONS The following adverse reactions associated with the use of BACTRIM or sulfamethoxazole and trimethoprim were identified in clinical trials, [0m
[31mpostmarketing or published reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or [0m
[31mestablish a causal relationship to drug exposure. The most common adverse reactions are gastrointestinal disturbances [0m[1;31m([0m[31mnausea, vomiting, anorexia[0m[1;31m)[0m[31m and allergic skin reactions [0m[1;31m([0m[31msuch as rash and [0m
[31murticaria[0m[1;31m)[0m[31m. BACTRIM: adverse_reactions: Fatalities and serious adverse reactions, including severe cutaneous adverse reactions [0m[1;31m([0m[31mSCARs[0m[1;31m)[0m[31m, including Stevens-Johnson syndrome, toxic epidermal necrolysis, [0m
[31mdrug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m, acute generalized erythematous pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m; fulminant hepatic necrosis; [0m
[31magranulocytosis, aplastic anemia and other blood dyscrasias; acute and delayed lung injury; anaphylaxis and circulatory shock have occurred with the administration of sulfamethoxazole and trimethoprim[0m
[31mproducts, including [0m[1;31mBACTRIM[0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. BACTRIM: adverse_reactions: Hematologic: Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic [0m
[31manemia, hypoprothrombinemia, methemoglobinemia, eosinophilia, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura. BACTRIM: adverse_reactions: Allergic Reactions: Stevens-Johnson [0m
[31msyndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like [0m
[31msyndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria, rash, periarteritis nodosa, systemic lupus [0m
[31merythematosus, drug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute generalized erythematous pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m, and acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mBACTRIM: adverse_reactions: Gastrointestinal: Hepatitis [0m[1;31m([0m[31mincluding cholestatic jaundice and hepatic necrosis[0m[1;31m)[0m[31m, elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, [0m
[31mpancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia. Genitourinary: Renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal insufficiency, [0m
[31moliguria and anuria, crystalluria and nephrotoxicity in association with cyclosporine. Metabolic and Nutritional: Hyperkalemia, hyponatremia [0m[1;31m([0m[31msee PRECAUTIONS: Electrolyte Abnormalities [0m[1;31m)[0m[31m, metabolic [0m
[31macidosis. Neurologic: Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache. Psychiatric: Hallucinations, depression, apathy, nervousness. BACTRIM: [0m
[31madverse_reactions: Endocrine: The sulfonamides bear certain chemical similarities to some goitrogens, diuretics [0m[1;31m([0m[31macetazolamide and the thiazides[0m[1;31m)[0m[31m and oral hypoglycemic agents. Cross-sensitivity may [0m
[31mexist with these agents. Diuresis and hypoglycemia have occurred. Musculoskeletal: Arthralgia, myalgia, rhabdomyolysis. Respiratory: Cough, shortness of breath and pulmonary infiltrates, acute [0m
[31meosinophilic pneumonia, acute and delayed lung injury, interstitial lung disease, acute respiratory failure [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cardiovascular System: QT prolongation resulting in ventricular tachycardia[0m
[31mand torsades de pointes , circulatory shock [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . Miscellaneous: Weakness, fatigue, insomnia.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the BACTRIM label do not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. However, gastrointestinal adverse [0m
[32mreactions such as nausea, emesis, abdominal pain, diarrhea, anorexia, and serious conditions like pancreatitis and pseudomembranous enterocolitis are listed among the possible adverse reactions to [0m
[32mBACTRIM. These gastrointestinal effects could potentially lead to hospitalization, but the extracts do not quantify the risk or directly link BACTRIM to an increased risk of gastrointestinal ulcer [0m
[32mhospitalization.[0m

[32mSOURCE: BACTRIM label[0m
[32mEXTRACT_START_END: The most common adverse reactions are gastrointestinal disturbances [0m[32m...[0m[32m pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the BACTRIM [0m
[34mlabel do not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. However, gastrointestinal adverse reactions such as nausea, emesis, abdominal pain, [0m
[34mdiarrhea, anorexia, and serious conditions like pancreatitis and pseudomembranous enterocolitis are listed among the possible adverse reactions to BACTRIM. These gastrointestinal effects could [0m
[34mpotentially lead to hospitalization, but the extracts do not quantify the risk or directly link BACTRIM to an increased risk of gastrointestinal ulcer hospitalization.[0m

[34mSOURCE: BACTRIM label[0m
[34mEXTRACT_START_END: The most common adverse reactions are gastrointestinal disturbances [0m[34m...[0m[34m pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether BACTRIM increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the BACTRIM label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. However, gastrointestinal adverse [0m
[32mreactions such as nausea, emesis, abdominal pain, diarrhea, anorexia, and serious conditions like pancreatitis and pseudomembranous enterocolitis are listed among the possible adverse reactions."[0m[32m,[0m
[32m      [0m[32m"The label does not quantify the risk or directly link BACTRIM to an increased risk of gastrointestinal ulcer hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for BACTRIM does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization. While gastrointestinal adverse reactions are listed as [0m
[32mpossible side effects, there is no direct information on the risk of hospitalization due to gastrointestinal ulcers."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether BACTRIM increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the BACTRIM label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. However, gastrointestinal adverse [0m
[34mreactions such as nausea, emesis, abdominal pain, diarrhea, anorexia, and serious conditions like pancreatitis and pseudomembranous enterocolitis are listed among the possible adverse reactions."[0m[34m,[0m
[34m      [0m[34m"The label does not quantify the risk or directly link BACTRIM to an increased risk of gastrointestinal ulcer hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for BACTRIM does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization. While gastrointestinal adverse reactions are listed as [0m
[34mpossible side effects, there is no direct information on the risk of hospitalization due to gastrointestinal ulcers."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does BACTRIM increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether BACTRIM increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the BACTRIM label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. However, gastrointestinal adverse reactions [0m
[31msuch as nausea, emesis, abdominal pain, diarrhea, anorexia, and serious conditions like pancreatitis and pseudomembranous enterocolitis are listed among the possible adverse reactions.[0m
[1;31m3[0m[31m. The label does not quantify the risk or directly link BACTRIM to an increased risk of gastrointestinal ulcer hospitalization.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for BACTRIM does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization. While gastrointestinal adverse reactions are [0m
[31mlisted as possible side effects, there is no direct information on the risk of hospitalization due to gastrointestinal ulcers.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for BACTRIM does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization. While gastrointestinal adverse reactions are listed as possible side [0m
[32meffects, there is no direct information on the risk of hospitalization due to gastrointestinal ulcers.[0m
